Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy

Rossi, Paolo Giorgi; Merito, Monica; Borgia, Piero

doi:10.1016/j.healthpol.2008.05.016

Cited by 17 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Hospital discharge databases, therefore, are the only source for a timely and inexpensive picture of the epidemiology of almost all severe diseases, as they provide a complete record of all hospitalizations, and include standardized diagnosis code lists that enable secular trend analysis of incident disease for a given population. Despite these advantages, hospital discharge databases are subject to some limitations that are common to all passive surveillance systems, such as under-diagnosis or deficiencies in reporting.…”

Section: Discussionmentioning

confidence: 99%

Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination strategies

Amodio¹,

Costantino²,

Boccalini

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Streptococcus pneumoniae is a major cause of human infectious diseases worldwide. Despite this documented evidence, data on pneumococcal disease rates among general populations are scant because of the frequent lack of cultural identification. In this study we propose a model for estimating the burden of pneumococcal pneumonia on hospitalizations. The study was performed by analyzing administrative and clinical data of patients aged 50 years or older, resident in Sicily, and hospitalized, from 2005 to 2012. Demographic information, admission/discharge dates, discharge status, and up to 6 discharge diagnoses coded according to ICD-9 CM were collected for each hospitalized patient. During the 8-year study period, a total of 72,372 hospitalizations with at least one ICD-9 CM diagnosis code suggestive of all-cause pneumonia were recorded. Of these, 1943 (2.7%) hospitalizations had specific ICD-9 CM diagnosis codes for pneumococcal pneumonia. According to the proposed model, 16,541 (22.9%) pneumonia out of all-cause pneumonia was estimated to be attributable to S. pneumoniae. Pneumococcal pneumonia and model-estimated pneumococcal pneumonia had mean hospitalization rates of 13.4 and 113.3/100,000, respectively, with a decreasing temporal trend. The risk of hospitalization for pneumococcal pneumonia was strongly correlated with age (P<0.001). Our model provides data usable to construct suitable decisional models for the decision-makers and could allow to the responsibles of healthcare facilities to assess the budget impact if they hypothesize to offer vaccination for pneumococcal disease to certain cohorts of subjects aged 50 years or older. In our area, the high estimated hospitalization rates among adults aged ≥65 years suggest the need to implement effective preventive strategies (e.g., vaccination) tailored for these groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination strategies

Amodio¹,

Costantino²,

Boccalini

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…2008 50 CEA (1) Immunisation(2) No immunisation DE Healthcare payer Birth cohort 83% Lifetime Cases averted & LYG Direct costs (2004, €) One-wayModel sensitive to herd immunity, vaccine efficacy and pneumonia events Cost/LYG:£67,696 (entire cohort without herd immunity)£25,711 (high risk) PD Ray et al. 2009 51 CEA (1) Immunisation(2) No immunisation US Healthcare (1) < 5 y(2) 5 y and over 76% (children born 2000–2002)85% (children born 2003–2006) 5 y Cases averted & LYS Direct costs (2006, US$) One-wayModel sensitive to disease incidence, herd immunity and hospital visits Cost/LYS:£141,633 (without herd immunity)£7,328 (with herd immunity) PD Giorgi- Rossi et al. 2009 52 CEA (1) Immunisation(2) No immunisation IT Public healthcare Birth cohort 12 m: 80%24 m: 82% 10 y Cases averted, LYG & DALY Direct costs (2005, €) One-way & PSAModel sensitive to disease incidence, mortality, vaccine price and vaccine efficacy Cost/LYG: £108,668Cost/DALY: £50,193Cost/averted case: £830 £172,324/ IPD£669,022/ meningitis£3,791,124/ death PD Claes et al.…”

Section: Resultsmentioning

confidence: 99%

Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review

Gibson¹,

Begum²,

Sigmundsson³

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This study compared the economic value of pediatric immunisation programmes for influenza to those for rotavirus (RV), meningococcal disease (MD), pneumococcal disease (PD), human papillomavirus (HPV), hepatitis B (Hep B), and varicella reported in recent (2000 onwards) cost-effectiveness (CE) studies identified in a systematic review of PubMed, health technology, and vaccination databases. The systematic review yielded 51 economic evaluation studies of pediatric immunisation — 10 (20%) for influenza and 41 (80%) for the other selected diseases. The quality of the eligible articles was assessed using Drummond's checklist. Although inherent challenges and limitations exist when comparing economic evaluations of immunisation programmes, an overall comparison of the included studies demonstrated cost-effectiveness/cost saving for influenza from a European-Union-Five (EU5) and United States (US) perspective; point estimates for cost/quality-adjusted life-years (QALY) from dominance (cost-saving with more effect) to ≤45,444 were reported. The economic value of influenza programmes was comparable to the other vaccines of interest, with cost/QALY in general considerably lower than RV, Hep B, MD and PD. Independent of the perspective and type of analysis, the economic impact of a pediatric influenza immunisation program was influenced by vaccine efficacy, immunisation coverage, costs, and most significantly by herd immunity. This review suggests that pediatric influenza immunisation may offer a cost effective strategy when compared with HPV and varicella and possibly more value compared with other childhood vaccines (RV, Hep B, MD and PD).

show abstract

“…Not incorporating herd protection in the analysis leads to an underestimation of the total effects of the childhood vaccination program. Two of the three studies on childhood PCV programs included in this review [13,26,31] did not consider herd protection [26,31], in a conservative approach. The third study appropriately considered herd protection for vaccine coverage of 80% [13].…”

Section: Discussionmentioning

confidence: 99%

“…Health system 5 Yes Cost Calculator No Pradas [21] Health system 5 Yes Dynamic No Jiang [24] Public payer 5 No Markov No Haasis [13] Health system 5 Yes Markov Yes Hoshi [26] Public payer 7 NI Markov No Giorgi-Rossi [31] Health system 10 No NI No Chit [12] (1) Health system [25] (1) Health system (2) Society 5…”

mentioning

confidence: 99%

Vaccines are different: A systematic review of budget impact analyses of vaccines

Loze

Nasciben

Sartori

et al. 2017

Vaccine

View full text Add to dashboard Cite

Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy

Cited by 17 publications

References 46 publications

Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination strategies

Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination strategies

Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review

Vaccines are different: A systematic review of budget impact analyses of vaccines

Contact Info

Product

Resources

About